Evidence map›Paper›PMID 42613799›Full record

ArticlemAbs2026

Mimic antibodies: leveraging ligand mimicry for epitope-targeted antibody discovery.

Brennan Abanades, Joanan Lopez-Morales, Ivan Tanasijevic, Cornelia Wagner, Janina Speck, Sebastian Fenn, Hubert Kettenberger, Joachim Butzer, Sarah Mundigl, Karolis Martinkus and 5 more

Abstract read
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Brennan AbanadesLarge Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.ORCID 0000-0001-8712-533X
Joanan Lopez-MoralesLarge Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
Ivan TanasijevicPrescient Design - AI for Drug Discovery, Computational Science Center of Excellence, Roche, Basel, Switzerland.
Cornelia WagnerLarge Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
Janina SpeckLarge Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
Sebastian FennLarge Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
Hubert KettenbergerLarge Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
Joachim ButzerLarge Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.ORCID 0009-0004-8109-9643
Sarah MundiglLarge Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
Karolis MartinkusPrescient Design - AI for Drug Discovery, Computational Science Center of Excellence, Roche, Basel, Switzerland.ORCID 0000-0002-5344-4321
Andreas LoukasPrescient Design - AI for Drug Discovery, Computational Science Center of Excellence, Roche, Basel, Switzerland.ORCID 0000-0003-4866-1599
Wing Ki WongLarge Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.ORCID 0000-0003-4029-6902
Homa MohammadiPeyhaniPrescient Design - AI for Drug Discovery, Computational Science Center of Excellence, Roche, Basel, Switzerland.ORCID 0000-0002-1308-4659
Bruno E CorreiaLaboratory of Protein Design and Immunoengineering, École Polytechnique Fédérale de Lausanne and Swiss Institute of Bioinformatics, Lausanne, Switzerland.ORCID 0000-0002-7377-8636
Anna VangoneLarge Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.ORCID 0000-0003-2485-7378

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibodies are renowned for their ability to bind diverse targets with high affinity and specificity, yet identifying binders with predefined epitope specificity remains a major challenge. In this study, we investigate the concept of mimic antibodies-antibodies that recapitulate the binding mode of a target's cognate ligand. Through a systematic analysis of the Protein Data Bank (PDB), we show that such mimicry is widespread and arises through diverse structural mechanisms, such as single-loop, multi-loop and scattered interaction mimicry. These findings indicate that protein interfaces impose strong constraints on binding, leading to convergent interaction solutions that can be independently discovered by antibodies. Building on these findings, we developed a ligand-guided strategy to mine immune repertoire data by selecting antibodies whose predicted binding interfaces mimic the interaction motif of a cognate ligand. Applied to the interaction between interleukin-18 (IL-18) and its receptor alpha (IL-18RA), mimicry-guided screening of a 20,000-sequence repertoire yielded 31 candidates, 11 of which (35% hit rate) bound the IL-18RA D3 domain, with eight reaching sub-nanomolar affinities that surpass the cognate ligand. Our findings establish mimic antibodies as a promising strategy for rational antibody selection, engineering, and design, with broad implications for therapeutic antibody development and drug discovery.

Indexed as

AntibodiesEpitopesInterleukin-18Molecular MimicryAnimalsDatabases, ProteinHumansLigandsProtein BindingAntibodiesEpitopesInterleukin-18LigandsAntibody repertoiredrug discoveryepitope targetingIL-18RAmimic antibodiesPDB analysisprotein mimicrysequence screeningtherapeutic antibodies

Identifiers

PMID42613799
PMCPMC13502006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.